MedPath

Optimizing Fluid Status

Not Applicable
Completed
Conditions
Hypotension During Dialysis
Registration Number
NCT01492634
Lead Sponsor
Francisco Maduell
Brief Summary

Title of study: Optimizing Fluid Status

Study code: HD-IIT-01-E

Study design: Prospective open design in study centre at two locations

Applied medical device: Body Composition Monitor (BCM) for determination of fluid overload and dry weight

Aim of the study: To improve the fluid status in chronic HD patients (measured as OH (overhydration) or TAFO (time averaged fluid overload)) based on BCM measurements. Up to now, the BCM was occasionally applied in both locations of the study centre.

Study hypothesis: Regular measurement of fluid status (assessed by BCM) and display of dry weight (post-weight plan)will have significant consequences, namely a decrease of the:

* time averaged fluid overload (TAFO),

* proportion of patients with severe overhydration OH \> 2.5 L,or OH/ECW \> 15 %)

* proportion of dehydrated patients (OH \< -1.0 L, or OH \< -7 %),

* mean overhydration,

* variance of overhydration,

* time outside the reference range (-1.0L \< OH \< 2.5L).

Devices used in this study: Dialysis machine 5008 equipped with Blood Pressure Monitor BPM, Blood Volume Monitor BVM, Blood Temperature Monitor BTM, and Online Clearance Monitor OCM ; Body Composition Monitor BCM ; Data management software / database system NephroLink Disposables used in this study: BVM blood lines and BCM electrodes

Patients: 60 patients

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
56
Inclusion Criteria
  • Chronic renal failure stage V
  • Treatment thrice weekly with HD or on-line HDF for at least 6 months prior to inclusion
  • Ability to understand the nature and requirements of the study
  • Age: at least 18 years
  • Signed informed consent.
Exclusion Criteria
  • Interventional clinical study during the preceding 30 days or previous participation in the same study
  • Acute or chronic infection (HIV, Hepatitis B or C, ...)
  • Severe disease (malignant tumour, tuberculosis ...)
  • Usually single needle HD
  • Problems with shunt or high recirculation,
  • Severe intra-dialytic blood pressure instability in the last month
  • Instable angina pectoris
  • Major amputation at arm or leg, or a pacemaker.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
intra-individual difference in TAFO between study start and study end3 months
Secondary Outcome Measures
NameTimeMethod
Comparison between start and end of treatment will be performed for Pre-dialytic overhydration (OH)3 months
Comparison between start and end of treatment will be performed for number of patients in target range (TAFO from -0.2 L to 1.3 L)3 months
SF 36 total score and sub-scores as calculated according to official guidelines,3 months
BNP3 months
Blood pressure3 months
laboratory parameters (sodium, calcium, potassium, chloride, haematocrit, haemoglobin, albumin, total protein, urea, creatinine, mean corpuscular volume, C-reactive protein, transferrin saturation, ferritin).3 months
Change from Baseline in Medication at 12 weeks (erythropoetin, iron, blood pressure medication)3 months
Change from baseline in intra-dialytic events (hypotension, cramps)3 months
Change from baseline in Residual Renal Function3 months

Baseline Residual renal function, measured as Kt/V residual, wil be compared with the Residual renal function at the end of 12 weeks.

Hospitalisation3 months

Trial Locations

Locations (1)

Dialysis Units, Hospital Clínic

🇪🇸

Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath